59
Participants
Start Date
August 16, 2022
Primary Completion Date
May 6, 2024
Study Completion Date
May 6, 2024
PF-07264660 intravenous single ascending dose
PF-07264660 will be administered intravenously in single ascending doses
PF-07264660 subcutaneous multiple ascending dose
PF-07264660 will be administered subcutaneously in multiple ascending doses
Intravenous placebo
Placebo will be administered intravenously in single ascending doses
subcutaneous placebo
Placebo will be administered subcutaneously in multiple ascending doses
Spaulding Clinical Research, West Bend
Prism Research LLC dba Nucleus Network, Saint Paul
Clinical Trials of Texas, LLC, San Antonio
Collaborative Neuroscience Research, LLC, Los Alamitos
Collaborative Neuroscience Research, LLC, Long Beach
Collaborative Neuroscience Research, LLC, Garden Grove
Lead Sponsor
Pfizer
INDUSTRY